Preparation of Tamsulosin Hydrochloride-Loaded Mucoadhesive In Situ Gelling Polymeric Formulation for Nasal Delivery in Geriatrics
© 2023. The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists..
This study aimed to prepare tamsulosin hydrochloride (HCl)-loaded in situ gelling formulation by using hydroxypropyl methylcellulose (HPMC), gellan gum, poloxamer 188, and benzalkonium chloride. Physicochemical evaluation of formulations included determination of pH, viscosity, gelation time, gel strength, drug content, and sterility. In silico study was performed to analyze interactions between polymers, drug, and mucin glycoprotein. In vitro degradation time, drug release, ex vivo mucoadhesion time, permeation, in vivo pharmacokinetics, and stability studies were performed to assess the formulation. Formulations were transparent and displayed acceptable physicochemical attributes. Tamsulosin HCl and polymers interacted via non-covalent interactions. HPMC formed hydrogen bonds, hydrophobic and van der Waals interactions with mucin protein while the drug formed hydrogen bonds only. Gel formulation degraded in simulated nasal fluid within 24 h. In situ gelling formulation showed 83.8 ± 1.7% drug release and remained adhered to the mucosa for 24.5 ± 1 h. A higher (~ 1.85 times) drug permeation was recorded through mucosa within 6 h by in situ gelling formulation when compared to control counterparts (aqueous solution of drug and in situ gelling formulation without poloxamer 188). Nasal administration of tamsulosin HCl by using in situ gelling formulation led to a ~ 3.3 and ~ 3.5 times, respectively, higher Cmax (maximum plasma concentration) and AUCtotal (total area under the curve) than the orally administered aqueous solution. Relative bioavailability of drug delivered by nasal in situ gelling formulation was 3.5 times the oral counterpart. These results indicated that the prepared in situ gelling formulation can act as a promising candidate for systemic administration of tamsulosin HCl.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
AAPS PharmSciTech - 24(2023), 8 vom: 28. Nov., Seite 242 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rana, Sadia Jafar [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
106392-12-5 |
|---|
| Anmerkungen: |
Date Completed 30.11.2023 Date Revised 29.12.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1208/s12249-023-02700-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365083763 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365083763 | ||
| 003 | DE-627 | ||
| 005 | 20240108140221.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1208/s12249-023-02700-x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1243.xml |
| 035 | |a (DE-627)NLM365083763 | ||
| 035 | |a (NLM)38017208 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rana, Sadia Jafar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Preparation of Tamsulosin Hydrochloride-Loaded Mucoadhesive In Situ Gelling Polymeric Formulation for Nasal Delivery in Geriatrics |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.11.2023 | ||
| 500 | |a Date Revised 29.12.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists. | ||
| 520 | |a This study aimed to prepare tamsulosin hydrochloride (HCl)-loaded in situ gelling formulation by using hydroxypropyl methylcellulose (HPMC), gellan gum, poloxamer 188, and benzalkonium chloride. Physicochemical evaluation of formulations included determination of pH, viscosity, gelation time, gel strength, drug content, and sterility. In silico study was performed to analyze interactions between polymers, drug, and mucin glycoprotein. In vitro degradation time, drug release, ex vivo mucoadhesion time, permeation, in vivo pharmacokinetics, and stability studies were performed to assess the formulation. Formulations were transparent and displayed acceptable physicochemical attributes. Tamsulosin HCl and polymers interacted via non-covalent interactions. HPMC formed hydrogen bonds, hydrophobic and van der Waals interactions with mucin protein while the drug formed hydrogen bonds only. Gel formulation degraded in simulated nasal fluid within 24 h. In situ gelling formulation showed 83.8 ± 1.7% drug release and remained adhered to the mucosa for 24.5 ± 1 h. A higher (~ 1.85 times) drug permeation was recorded through mucosa within 6 h by in situ gelling formulation when compared to control counterparts (aqueous solution of drug and in situ gelling formulation without poloxamer 188). Nasal administration of tamsulosin HCl by using in situ gelling formulation led to a ~ 3.3 and ~ 3.5 times, respectively, higher Cmax (maximum plasma concentration) and AUCtotal (total area under the curve) than the orally administered aqueous solution. Relative bioavailability of drug delivered by nasal in situ gelling formulation was 3.5 times the oral counterpart. These results indicated that the prepared in situ gelling formulation can act as a promising candidate for systemic administration of tamsulosin HCl | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Benign prostate hyperplasia | |
| 650 | 4 | |a In situ gelling mucoadhesive formulation | |
| 650 | 4 | |a Nasal drug delivery | |
| 650 | 4 | |a Polymeric system | |
| 650 | 4 | |a Tamsulosin hydrochloride | |
| 650 | 7 | |a Tamsulosin |2 NLM | |
| 650 | 7 | |a G3P28OML5I |2 NLM | |
| 650 | 7 | |a Poloxamer |2 NLM | |
| 650 | 7 | |a 106392-12-5 |2 NLM | |
| 650 | 7 | |a Mucins |2 NLM | |
| 650 | 7 | |a Gels |2 NLM | |
| 700 | 1 | |a Zafar, Saman |e verfasserin |4 aut | |
| 700 | 1 | |a Shahzad, Aqeel |e verfasserin |4 aut | |
| 700 | 1 | |a Basit, Muhammad |e verfasserin |4 aut | |
| 700 | 1 | |a Mudassir, Jahanzeb |e verfasserin |4 aut | |
| 700 | 1 | |a Akhlaq, Muhammad |e verfasserin |4 aut | |
| 700 | 1 | |a Chohan, Tahir Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Arshad, Muhammad Sohail |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t AAPS PharmSciTech |d 2000 |g 24(2023), 8 vom: 28. Nov., Seite 242 |w (DE-627)NLM126699429 |x 1530-9932 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2023 |g number:8 |g day:28 |g month:11 |g pages:242 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1208/s12249-023-02700-x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2023 |e 8 |b 28 |c 11 |h 242 | ||